Literature DB >> 22328271

Histone deacetylase modulators provided by Mother Nature.

Carole Seidel1, Michael Schnekenburger, Mario Dicato, Marc Diederich.   

Abstract

Protein acetylation status results from a balance between histone acetyltransferase and histone deacetylase (HDAC) activities. Alteration of this balance leads to a disruption of cellular integrity and participates in the development of numerous diseases, including cancer. Therefore, modulation of these activities appears to be a promising approach for anticancer therapy. Histone deacetylase inhibitors (HDACi) are epigenetically active drugs that induce the hyperacetylation of lysine residues within histone and non-histone proteins, thus affecting gene expression and cellular processes such as protein-protein interactions, protein stability, DNA binding and protein sub-cellular localization. Therefore, HDACi are promising anti-tumor agents as they may affect the cell cycle, inhibit proliferation, stimulate differentiation and induce apoptotic cell death. Over the last 30 years, numerous synthetic and natural products, including a broad range of dietary compounds, have been identified as HDACi. This review focuses on molecules from natural origins modulating HDAC activities and presenting promising anticancer activities.

Entities:  

Year:  2012        PMID: 22328271      PMCID: PMC3380189          DOI: 10.1007/s12263-012-0283-9

Source DB:  PubMed          Journal:  Genes Nutr        ISSN: 1555-8932            Impact factor:   5.523


  76 in total

1.  Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera.

Authors:  Il Hong Son; Ill-Min Chung; Sung Ik Lee; Hyun Duk Yang; Hyung-In Moon
Journal:  Bioorg Med Chem Lett       Date:  2007-06-26       Impact factor: 2.823

2.  Insights into the sirtuin mechanism from ternary complexes containing NAD+ and acetylated peptide.

Authors:  Kevin G Hoff; José L Avalos; Kristin Sens; Cynthia Wolberger
Journal:  Structure       Date:  2006-08       Impact factor: 5.006

3.  Inhibition of Sirt1 promotes neural progenitors toward motoneuron differentiation from human embryonic stem cells.

Authors:  Yun Zhang; Jing Wang; Guian Chen; Dongsheng Fan; Min Deng
Journal:  Biochem Biophys Res Commun       Date:  2010-12-07       Impact factor: 3.575

4.  Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin.

Authors:  J W Han; S H Ahn; S H Park; S Y Wang; G U Bae; D W Seo; H K Kwon; S Hong; H Y Lee; Y W Lee; H W Lee
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

5.  Psammaplin A is a natural prodrug that inhibits class I histone deacetylase.

Authors:  Dong Hoon Kim; Jongheon Shin; Ho Jeong Kwon
Journal:  Exp Mol Med       Date:  2007-02-28       Impact factor: 8.718

6.  Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.

Authors:  Lin Gao; Maria A Cueto; Fred Asselbergs; Peter Atadja
Journal:  J Biol Chem       Date:  2002-04-10       Impact factor: 5.157

7.  The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

Authors:  Roberto R Rosato; Jorge A Almenara; Steven Grant
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

8.  Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin.

Authors:  Stefanie De Schepper; Hélène Bruwiere; Tinne Verhulst; Ulf Steller; Luc Andries; Walter Wouters; Michel Janicot; Janine Arts; Jim Van Heusden
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

9.  Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function.

Authors:  Shashwati Basak; Deepa Pookot; Emily J Noonan; Rajvir Dahiya
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

10.  Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.

Authors:  Yongcheng Ying; Kanchan Taori; Hyoungsu Kim; Jiyong Hong; Hendrik Luesch
Journal:  J Am Chem Soc       Date:  2008-05-29       Impact factor: 15.419

View more
  15 in total

1.  Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.

Authors:  Sophia N Ononye; Michael D VanHeyst; E Zachary Oblak; Wangda Zhou; Mohamed Ammar; Amy C Anderson; Dennis L Wright
Journal:  ACS Med Chem Lett       Date:  2013-06-10       Impact factor: 4.345

2.  Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest.

Authors:  Patrick M Long; Scott W Tighe; Heather E Driscoll; Karen A Fortner; Mariano S Viapiano; Diane M Jaworski
Journal:  J Cell Physiol       Date:  2015-08       Impact factor: 6.384

Review 3.  Small molecule inhibitors of zinc-dependent histone deacetylases.

Authors:  Florence F Wagner; Michel Weїwer; Michael C Lewis; Edward B Holson
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 4.  The complexity of the Nrf2 pathway: beyond the antioxidant response.

Authors:  Ying Huang; Wenji Li; Zheng-yuan Su; Ah-Ng Tony Kong
Journal:  J Nutr Biochem       Date:  2015-08-08       Impact factor: 6.048

5.  Epigenetically induced changes in nuclear textural patterns and gelatinase expression in human fibrosarcoma cells.

Authors:  M Poplineau; C Doliwa; M Schnekenburger; F Antonicelli; M Diederich; A Trussardi-Régnier; J Dufer
Journal:  Cell Prolif       Date:  2013-04       Impact factor: 6.831

6.  Natural chalcones as dual inhibitors of HDACs and NF-κB.

Authors:  B Orlikova; M Schnekenburger; M Zloh; F Golais; M Diederich; D Tasdemir
Journal:  Oncol Rep       Date:  2012-06-15       Impact factor: 3.906

Review 7.  Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.

Authors:  Amit Kumar Singh; Anupam Bishayee; Abhay K Pandey
Journal:  Nutrients       Date:  2018-06-06       Impact factor: 5.717

8.  Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.

Authors:  Manon Lernoux; Michael Schnekenburger; Hélène Losson; Koen Vermeulen; Hyunggu Hahn; Déborah Gérard; Jin-Young Lee; Aloran Mazumder; Muneer Ahamed; Christo Christov; Dong-Wook Kim; Mario Dicato; Guy Bormans; Byung Woo Han; Marc Diederich
Journal:  Clin Epigenetics       Date:  2020-05-19       Impact factor: 6.551

Review 9.  The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus.

Authors:  Saikat Dewanjee; Jayalakshmi Vallamkondu; Rajkumar Singh Kalra; Pratik Chakraborty; Moumita Gangopadhyay; Ranabir Sahu; Vijaykrishna Medala; Albin John; P Hemachandra Reddy; Vincenzo De Feo; Ramesh Kandimalla
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

10.  Differential cellular and molecular effects of butyrate and trichostatin a on vascular smooth muscle cells.

Authors:  Shirlette G Milton; Omana P Mathew; Frank M Yatsu; Kasturi Ranganna
Journal:  Pharmaceuticals (Basel)       Date:  2012-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.